Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$8.65 ▼ -0.02
(-0.23%)
MKT CAP: $661.9M • VOL: 741.0K
52W L $4 52W H $14
ROARABLE / RQD
D- • 38/100
PIOTROSKI
2 / 9
CADL // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$48.3M | -$33.4M | -$38.4M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$38.2M | -$55.2M | -$37.9M |
| EBITDA (Normalized) | -$47.8M | -$33.4M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$38.3M | -$27.0M | -$34.2M |
| Capital Expenditures (CapEx) | $587.0K | $16.0K | — |
| Free Cash Flow (FCF) | -$38.9M | -$27.0M | -$34.2M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $119.7M | $102.7M | — |
| Total Debt (Short + Long Term) | — | $1.7M | — |
| Total Stockholders' Equity | $51.9M | $66.3M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CADL.